ERBB2 and glioblastoma: In a 3 + 3 dose escalation Phase I clinical trial (CAR2BRAIN; NCT0338978), patients with recurrent HER2-positive glioblastoma, with an already scheduled relapse resection surgery, received 1 × 107, 3 × 107 or 1 × 108 ErbB2-NK-92/5.28z CAR-NK cells/2ml injected intracranially.